Proteomics International Laboratories Ltd. announced it has secured CE Mark registration for the PromarkerD Hub as an IVD medical device (in vitro diagnostic). PromarkerD Hub is a software tool used to calculate the risk of kidney disease in patients with type 2 diabetes. It forms part of the PromarkerD # test system which is the only test available in the Europe Union (EU) for predicting the onset of diabetic kidney disease (DKD). CE marking of the PromarkerD Hub complements the recent CE registration of the mass spectrometry version of the test, PromarkerD (MS).